PHILADELPHIA, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Grabar Law Office is investigating claims on behalf of PACS Group, Inc. (NYSE: PACS) shareholders. The investigation concerns whether certain officers and directors of PACS breached the fiduciary duties they owed to the company. If you are a current shareholder who purchased PACS Group shares on or near the Company’s April 11, 2024 IPO, you can seek corporate reforms, the return of money back to the company, and a court approved incentive award at no cost to you whatsoever.Please visit https://grabarlaw.com/the-latest/pacs-shareholder-investigation/, contact Joshua Grabar at [email protected], or call us at 267-507-6085 WHY? On November 4, 2024, investment research firm Hindenburg Research published a report that accused PACS Group, Inc. (NYSE:PACS) of engaging in fraudulent practices. A federal securities fraud class action Complaint soon followed in which it is alleged that in the Registration Statement and throughout the Class Period (April 11, 2024 to November 5, 2024), PACS Group, through certain of its officers, made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, it is alleged that Defendants failed to disclose to investors: (1) that the Company engaged in a “scheme” to submit false Medicare claims which “drove more than 100% of PACS’ operating and net income from 2020 – 2023”; (2) that the Company engaged in a “scheme” to “bill thousands of unnecessary respiratory and sensory integration therapies to Medicare”; (3) that the Company engaged in a scheme to falsify documentation related to licensure and staffing; and (4) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. WHAT YOU CAN DO NOW: If you purchased PACS Group shares on or near the April 11, 2024 IPO, you are encouraged to visit https://grabarlaw.com/the-latest/pacs-shareholder-investigation/, contact Joshua Grabar at [email protected], or call 267-507-6085. You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. Attorney Advertising Disclaimer Contact: Joshua H. Grabar, Esq. Grabar Law Office One Liberty Place 1650 Market Street, Suite 3600 Philadelphia, PA 19103 Tel: 267-507-6085 Email: [email protected]
PACS Group, Inc. (NYSE: PACS) Shareholder Notice: Grabar Law Office Is Investigating Claims on Your Behalf
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...